Impact of Subsequent Allogeneic Hematopoietic Stem Cell Transplant (HSCT) on Overall Survival (OS) Outcomes in the Quazar AML-001 Trial of Oral Azacitidine (CC-486) Maintenance Therapy for Patients with Acute Myeloid Leukemia (AML) in First Remission Who Were Not Eligible for HSCT at Study Entry
2021 TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR（2021）
关键词
acute myeloid leukemia,oral azacitidine,transplant,overall survival
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要